Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement

Advertisement

Videos

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

News

FDA Approves Cemiplimab-rwlc and Expands Approval of Companion Diagnostic in NSCLC

Medical Literature

Examining Treatment Resistance in RET Fusion–Positive NSCLC

News

WCLC 2020: 5-Year Survival Update on Pembrolizumab Versus Docetaxel in NSCLC

News

WCLC 2020: Genomic Analysis of Women With Lung Cancer Who Never Smoked

News

WCLC 2020: Novel Tyrosine Kinase Inhibitor Versus Chemotherapy for EGFR-Mutated NSCLC

Medical Literature

Study Finds Ethnic Association With Oncogenic Mutations for Patients With Lung Carcinoma

Misako Nagasaka, MD, on Sintilimab Plus Chemotherapy for Advanced Nonsquamous Lung Cancer

Roy S. Herbst, MD, PhD, on Osimertinib for NSCLC: Clinical Implications of a Potentially Practice-Changing Finding

View More

Advertisement

JNCCN Spotlights

Dabrafenib + Trametinib (Tafinlar + Mekinist)

Crizotinib (Xalkori)

Pembrolizumab (Keytruda) in NSCLC

Nivolumab (Opdivo) in NSCLC

Afatinib (Gilotrif)

View More

More

News

SITC 2020: Bemcentinib and Pembrolizumab in Stage IV Lung Adenocarcinoma

Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

WCLC 2020: Small-Molecule Inhibitor Active in KRAS G12C–Mutated NSCLC

ASTRO 2020: Stereotactic Body Radiotherapy With and Without Pembrolizumab Under Study in Lung Cancer

Lorlatinib for First-Line Treatment of ALK-Positive NSCLC

Can Chemoimmunotherapy Achieve Pathologic Downstaging in Resectable Lung Cancer?

WCLC 2020: Patient-Reported Outcomes With Lorlatinib Versus Crizotinib in ALK-Positive NSCLC

View More

Advertisement

Published

Medical Literature

Osimertinib or Platinum/Pemetrexed in EGFR T790M–Positive Lung Cancer

Heat Shock Protein 90 Inhibitor in Lung Cancer: GALAXY Clinical Trials

Multikinase Inhibitors in RET-Rearranged NSCLC

Addition of Selumetinib to Docetaxel in KRAS-Mutant Lung Cancer

View More

Ongoing

CE Activities

Advanced Non-Small Cell Lung Ccancer Patient Management Simulator

Novel and Emerging Therapeutic Strategies in the Management of Non–Small Cell Lung Cancer

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Consensus or Controversy? Addressing Practical Clinical Questions Across the Metastatic Lung Cancer Continuum

View More

Available

Clinical Trials

City of Hope Comprehensive Cancer Center

Cleveland Clinic Taussig Cancer Institute

Fox Chase Cancer Center

Fred and Pamela Buffett Cancer Center

View More

Resources

For Your Patients

The American Lung Association

Bonnie J. Addario Lung Cancer Foundation

Caring Ambassadors Program

Dusty Joy Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.